Evolus, Inc. (EOLS) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Newport Beach, CA, United States. The current CEO is David Moatazedi.
EOLS has IPO date of 2018-02-08, 372 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $288.87M.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
